Immune-targeting vaccine shows promise intercepting cancer in patients with Lynch Syndrome

The investigational cancer vaccine, NOUS-209, was found to safely stimulate the immune system to target precancerous and cancerous cells in individuals with Lynch Syndrome (LS), according to a study from researchers at The University of Texas MD…

Continue Reading

News Source: medicalxpress.com